Christie Ballantyne, MD

Articles by Christie Ballantyne, MD

Closing Thoughts on ASCVD Management

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 12th 2026

Experts reveal how risk assessment, LDL-C targets, and smarter follow-up boost adherence—turning guidelines into real cardiovascular prevention.

Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 5th 2026

Learn how clinicians reach ultra-low LDL targets in high-risk patients using ezetimibe, PCSK9s, and smarter insurance documentation.

Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 5th 2026

Why patients quit cholesterol therapy—and how LDL checkups, reminders, and longer-acting injectables improve lifelong medication adherence.

Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 29th 2026

Compare statins, ezetimibe, bempedoic acid and PCSK9 inhibitors for side effects, dosing preferences, and shared decision-making tips.

Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 29th 2026

Compare statin side effects with ezetimibe, bempedoic acid and PCSK9 inhibitors, plus practical dosing tips and shared decision-making.

Advancing ASCVD Management with PCSK9 Inhibitors

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 22nd 2026

Explore where ezetimibe and bempedoic acid fit for statin‑reluctant patients, lowering LDL with proven outcomes and diabetes benefits.

The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 22nd 2026

Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 15th 2026

See how coronary calcium images and risk graphs boost engagement, drive LDL-lowering choices, and help more patients reach cholesterol goals.

Driving Patient Engagement in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 15th 2026

Navigating Combination Therapy and Access Challenges in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 8th 2026

Learn how clinicians personalize LDL-lowering therapy, address statin fears, and choose pills or injections to hit cholesterol goals despite cost barriers.

Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 8th 2026

Clinicians shift from “hyper” labels to atherosclerosis risk, using diabetes markers and LDL targets to prevent heart attack and stroke.

Examining the 2026 ACC/AHA Dyslipidemia Guidelines for ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 1st 2026

ASCVD Risk Assessment and LDL-C Management

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 1st 2026

RX Review: Leveraging siRNA in FCS Management

RX Review: Barriers, Real-World Implementation, and Future Directions in FCS

ByViet Le, DMSc, PA-C,Christie Ballantyne, MD

November 26th 2025

RX Review: Monitoring and Safety Considerations in FCS

ByViet Le, DMSc, PA-C,Christie Ballantyne, MD

November 26th 2025

Explore the critical role of nutrition and pharmacologic therapies in managing hypertriglyceridemia and preventing pancreatitis effectively.

RX Review: Integrating New Therapies in FCS Treatment Algorithms

ByViet Le, DMSc, PA-C,Christie Ballantyne, MD

November 26th 2025

Explore how the latest FDA approvals impact the management of FCS.

RX Review: Understanding Plozasiran’s Role in FCS Management

ByViet Le, DMSc, PA-C,Christie Ballantyne, MD

November 26th 2025

Panelists break down the potential role of plozasiran in FCS based on the PALISADE trial.

RX Review: Updates in Diagnosis and Testing for FCS

ByViet Le, DMSc, PA-C,Christie Ballantyne, MD

November 26th 2025

Understanding severe hypertriglyceridemia is crucial for preventing pancreatitis and managing triglyceride levels effectively.

RX Review: Delays, Clinical Features, and Raising Awareness for FCS

ByViet Le, DMSc, PA-C,Christie Ballantyne, MD

November 26th 2025

Discover effective strategies to shorten the diagnostic window for pancreatitis and manage high triglyceride levels in FCS.

RX Review: Updates and Unmet Needs for Familial Chylomicronemia Syndrome

ByViet Le, DMSc, PA-C,Christie Ballantyne, MD

November 26th 2025

Explore the challenges and advancements in managing FCS with expert insights on treatment and patient care.

Triglyceride Management and Pancreatitis Risk, With Christie M. Ballantyne, MD

ByChristie Ballantyne, MD

April 22nd 2025

Christie M. Ballantyne, MD, discusses the role of plozasiran in managing elevated triglycerides and reducing pancreatitis risk.

Clinical Pearls on Lipid Management

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.

Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.

The Role of Lipoprotein A in Lipid Lowering

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.

Long-term efficacy and safety of PCSK9 inhibitors

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.

Starting Combination Therapy Early

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

October 5th 2023

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Nonstatin Lipid-Lowering Agents

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

October 5th 2023

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

Statin Intolerance

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 28th 2023

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.